Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $2.6 million.

  • Viridian Therapeutics, Inc.\DE's Other Non-Current Liabilities rose 1948.17% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 1948.17%. This contributed to the annual value of $2.3 million for FY2024, which is 13336.7% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Other Non-Current Liabilities stood at $2.6 million for Q3 2025, which was up 1948.17% from $2.1 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Other Non-Current Liabilities high stood at $2.6 million for Q3 2025, and its period low was $33000.0 during Q1 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Other Non-Current Liabilities value was $1.2 million (recorded in 2021), while the average stood at $1.4 million.
  • Data for Viridian Therapeutics, Inc.\DE's Other Non-Current Liabilities shows a peak YoY increase of 311212.12% (in 2022) and a maximum YoY decrease of 6426.37% (in 2022) over the last 5 years.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Other Non-Current Liabilities (Quarter) stood at $1.2 million in 2021, then fell by 2.98% to $1.2 million in 2022, then decreased by 15.61% to $989000.0 in 2023, then skyrocketed by 133.37% to $2.3 million in 2024, then increased by 11.87% to $2.6 million in 2025.
  • Its Other Non-Current Liabilities was $2.6 million in Q3 2025, compared to $2.1 million in Q2 2025 and $1.9 million in Q1 2025.